Solute carrier family 34 member 2 (SLC34A2) belongs to the solute carrier gene family and is mapped to human chromosome 4p15.2. The gene codes for the type II Na/Pi co-transporter, NaPi2b. The encoded protein contains 690 amino acids. SLC34A2 is mainly localized on cell surfaces as a heavily glycosylated plasma membrane protein.
Synonyms: Anti-NAPI-3B; Anti-Solute carrier family 34 (sodium phosphate), member 2
Storage: -20C
Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Biochem Physiol Actions: Sodium-dependent phosphate transport protein 2B (NaPi-2b), encoded by solute carrier family 34 member 2 (SLC34A2), is a multi-transmembrane sodium-dependent phosphate transporter. The protein plays a vital role in various cellular functions including transcellular inorganic phosphate absorption, maintenance of phosphate homeostasis, and tumorigenesis. Elevated expression of SLC34A2 is observed in ovarian cancer and papillary thyroid cancer, but decreased expression of the gene is observed in human non-small cell lung carcinomas. In addition, overexpression of SLC34A2 might also be implicated in the development of breast cancer. Hence, this gene might act as a potential therapeutic target and marker for diagnosis of breast cancer. Knockdown of SLC34A2 gene suppress proliferation and invasion of hepatocellular carcinoma (HCC) cells, by inhibiting the phosphatidylinositol-3-kinase (PI3K)/Akt signaling pathway.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC